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Aims: Angiotensin converting enzyme(ACE) inhibition reduces mortality and morbidity in 
patients with heart failure after acute myocardial infarction(AMI). However, there are limited 
randomised data about the long-term survival benefits of ACE inhibition in this population.  
Methods: In 1993 the Acute Infarction Ramipril Efficacy(AIRE) study randomly allocated 
patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial 
therapy in the UK cohort(603 patients, mean age = 64.7 years, 455 male patients) was 12.4 
and 13.4 months for ramipril(n=302) and placebo(n=301), respectively. We estimated life 
expectancy and extensions of life(difference in median survival times) according to duration 
of follow-up (range 0 to 29.6 years).  
Results: By 9th April 2019, death from all causes occurred in 266 (88.4%) patients in placebo 
arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and 
placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy 
more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), 
previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension 
(16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). 
Given potential treatment switching, the true absolute treatment effect could be 
underestimated by 28%.  
Conclusion: For patients with clinically defined heart failure following AMI, ramipril results in 
a sustained survival benefit, and is associated with an extension of life of up to 14.5 months 
for, on average, 13 months treatment duration.  
Key Words: Myocardial infarction, heart failure, ramipril, ACE inhibition, survival, extension of 
life. 
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Running Title  AIRE-S Study 
Key messages 
 
What is already known about this subject? 
 
Angiotensin converting enzyme (ACE) inhibition reduces mortality and morbidity in patients 
with heart failure after acute myocardial infarction (AMI). However, there are limited 
randomised data about the long-term survival benefits of ACE inhibition in this population. 
 
What does this study add? 
 
This study demonstrates that treatment with ramipril for about one year, when started early 
post AMI in patients with heart failure results in a survival benefit which is sustained over 
many years and offers, on average, an extension of life of an additional one year. 
 
How might is impact on clinical practice? 
 
This study provided the evidence of long-term survival benefit of ACE inhibition in patients 





Survival following acute myocardial infarction (AMI) remains a key objective for healthcare 
professionals and governments throughout the globe. Despite major advances in the 
emergency treatment and secondary prevention of AMI, a substantial proportion of patients 
with AMI develop heart failure,1 which in turn is associated with high morbidity, mortality and 
healthcare expenditure.2-4 
 
Moreover, therapeutic inhibition of angiotensin converting enzyme (ACE) has become an 
established strategy in the care of patients with AMI and heart failure.5 ACE inhibition reduces 
death and disease in patients with left ventricular systolic dysfunction, and coronary artery 
disease.6-9 In the Acute Infarction Ramipril Efficacy (AIRE) study, ACE inhibition at an average 
follow-up time of 15 months after randomisation significantly reduced all-cause mortality, and 
continued to confer a survival benefit at 3 years following study closure in the AIRE Extension 
(AIREX) study.10, 11 Further placebo-controlled survival studies testing the efficacy of ACE 
inhibition in patients with AMI and clinical heart failure are unlikely because withholding a 
treatment of accepted clinical value would be unethical. Therefore, in the acute infarction 
ramipril efficacy survival (AIRE-S) study, we aimed to assess the longer-term (29.6 years after 
randomisation) magnitude of impact on length of survival observed after treatment with 




Patients and design 
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The rationale, design, organisation, outcome definitions and results of the AIRE study have 
been published previously.10, 12 This was an independent, multinational, multicentre, double-
blind, randomized, placebo-controlled, parallel-group investigation into the potential benefits 
from treatment with the lipophilic ACE-inhibitor ramipril (target dose 10mg/day) following 
AMI complicated by clinical evidence of heart failure. When the trial was conducted, in 1993, 
all patients had an ECG and cardiac enzyme confirmation of AMI, and also evidence of 
transient or persisting heart failure as judged by the attending physician (chest x-ray evidence 
of left ventricular failure, or auscultatory evidence of pulmonary oedema, or a third heart 
sound in the presence of persistent tachycardia), usually sufficient to justify diuretic or 
vasodilator therapy. Patients were excluded if they had evidence of clinical instability, contra-
indications to the use of ACE-inhibitor therapy, heart failure of primary valvular or congenital 
origin, or overt heart failure deemed to require treatment with an open-label ACE-inhibitor. 
After applying these entry criteria to consecutive patients admitted to the UK centres (30 
centres), 44% of patients approached declined to give their consent to take part in the study.  
All 603 of the remaining patients were then randomised by telephone to receive masked 
treatment with either ramipril (titrated over 4 days to 5mg twice daily) or a matching placebo. 
Treatment was started between two days and nine days after the onset of AMI. Patients 
initially received either 1.25 mg or 2.5 mg Ramipril or identical placebo twice daily, titrating 
to a maintenance dose of either 2.5 mg or 5 mg twice daily. No pre-randomization assessment 
of tolerance was undertaken. Thus, the trial set out to test the specific clinical strategy of the 
intention to treat patients with the appropriate blinded trial therapy. As a result of not 
excluding patients shown to be intolerant to treatment, 86.4% of patients were taking ramipril 
(2.5mg b.i.d. ; 7.9% & 5mg b.i.d.; 78.5%) and 94.7% were taking placebo (2.5 mg b.i.d.; 4.2% 
& 5mg b.i.d. 90.5%) when discharged from hospital. At the time of the AIRE Study close 
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(midnight on 28th February 1993) double-bind, randomised treatment was still being taken by 
46% and 48.5% of patients randomised to receive ramipril and placebo respectively Table 1. 
Thereafter, the use of ACE-inhibitor therapy was open label and guided by clinical discretion 
based on the evidence-base available at that time. Clinicians were still blinded to randomised 
treatment allocation at that time and also for the following 6 months beyond study close. 
 
For the AIRE-S study, we accessed the National Health Service Spine on 9th April 2019 to obtain 
information on all-cause mortality for all UK participants. For AIRE study, an independent 
adjudicating panel acted as the overall ethical supervisory body and had access to the 
randomisation code.10 For AIREX study, 603 patients in the UK provided informed consent. 
Ethical permission was obtained from each centre, and mortality information was accessed 
through Office for National Statistics.11 
 
This is a secondary analyses of long-term follow-up cohort, therefore an ethics approval is not 
required and patients were not involved in this study. The study complies with the Declaration 
of Helsinki. 
Statistical Analyses 
The statistical significance for differences in the proportion of patients with differing reasons 
for cessation of randomized treatment were compared for placebo and ramipril groups using 
the Fisher’s Exact test. Kaplan Meier survival curves were constructed and clinical subgroups 
were compared using the Log Rank test where the survival curves did not cross over. 
Restricted mean survival time (RMST) was used to measure the average survival time from 
randomisation to any follow up time point.13, 14 Restricted mean survival time was chosen to 
model the data because the survival curves of the ramipril and placebo groups crossed over 
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during follow up and the hazard ratio was time dependent. A superficial interpretation is that 
after a while, ramipril may start to become hazardous. The RMST is equivalent to the area 
under the Kaplan-Meier curve from the randomisation up to that time point, and can be 
interpreted as life expectancy.15 Life expectancy difference (LED, the difference between the 
RMSTs) and life expectancy ratio (LER, the ratio between the RMSTs) were calculated for each 
time point to quantify the treatment effects of ramipril, and may be interpreted as absolute 
and relative gains or losses in life expectancy. The RMST was calculated separately for ramipril 
and placebo groups using numerical integration of the modelled survival curve obtained using 
a flexible parametric model adjusted for the baseline patient characteristics (age, sex, past 
medical history and type of AMI).  
 
The median lifetime, represented by the median survival time, was estimated from the 
Kaplan-Meier curves. Extension of life was calculated by subtraction of the two median 
lifetimes for the ramipril and placebo groups. The nonparametric two-sample procedure for 
comparing survival quantiles was used to compare the difference in the median survival times 
for patients allocated to placebo or ramipril.16  
 
Given the original AIRE study demonstrated a substantial survival benefit of ramipril treatment 
for patients with AMI and heart failure at the study closure, it is likely that patients in placebo 
group may have subsequently been switched to receive ramipril treatment. Therefore, the 
counterfactual survival times, due to treatment switching after study closure, were estimated 
by fitting a rank preserving structural failure time model.17, 18 This was undertaken for a 
combination of hypothetical scenarios including a range of proportions of patients in the 
placebo arm switching to the treatment and a range of proportions of patients in the ramipril 
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arm switching to the placebo arm (which was based on data for those patients who refused 
treatment or had drug intolerances in the AIRE study in Table 1). Patients in the placebo arm 
were assumed to switch to ramipril or another ACE inhibitor within 5 years after the study 
closure with uniform distribution of switching times and were assumed a treatment effect 
equal to that of the ramipril group. Adjusted hazard ratios were estimated for each scenario 
every 5 years from the time of randomisations for 25 years, and 95% confidence intervals (CI) 
estimated through bootstrapping.  
All analyses were performed based on intention-to-treat except for modelling the 
hypothetical treatment switching. Statistical analyses and data management were performed 
in R version 3.5.1.  
 
Results 
The survival status at 27.6 years after close of the AIRE study was ascertained for all 603 
patients recruited within the UK. As described previously, the two groups were well matched 
with a mean age of 64.7 (sd 9.6) years (Supplement Table 1). Blinded trial medication was 
taken by patients for an average of 12.9 months (ramipril 12.4 months; placebo 13.4 months) 
(Table 1). Treatment withdrawal due to intolerance (21.9% vs. 9.3%, p<0.001) and patient 
refusal (9.3% vs. 3.3%, p=0.002) was higher in the ramipril group, and higher as a result of 
death (11.0% vs 6.3%, p=0.021) or development of severe clinical heart failure (13.6% vs. 7.3%, 
p=0.008) in the placebo group.  
 
At the time of censorship (9th April 2019), there were 18 (2.9%) patients who were lost to 
follow up. In total, there were 541 (89.7%) deaths (266 deaths in placebo group and 275 
deaths in ramipril group) over a median time of death of 7.9 years (range 0.0 to 28.7 years) 
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after recruitment, representing 4945.2 patient years follow up, between 0 and 29.6 years of 
study follow up. Survival at the end of study follow-up was not different between the ramipril 
and placebo groups (HR 0.96, 95% CI 0.81 to 1.15, Figure 1) because more-or-less all patients 
had died at the end of follow-up. Similar trends were evident when the survival was stratified 
by patient characteristics (Figure 2). 
 
The median survival time was 8.3 years (95% CI: 6.2 to 10.2 years) for placebo group and 9.6 
years (95% CI: 8.3 to 10.9 years) for ramipril group. The extension of life between ramipril and 
placebo groups, measured by the difference in median survival time, was 14.5 (95% CI 13.2 to 
15.8) months. The survival curves crossed at 14 years from the time of randomisation and the 
life expectancy difference between ramipril and placebo groups was greatest at about 15 
years from the time of randomisation (LED 11.6 months, 95%CI 0.7 to 22.6) (Figure 3). The 
magnitude of the LER was largest at around 7 years from the time of randomisation (1.14, 95% 
CI 1.05 to 1.23). At the end of follow-up, the LED and LER between ramipril and placebo was 
7.4 months (95% CI -10.0 to 24.9) and 1.06 (95% CI 0.93 to 1.21), respectively. 
 
Ramipril treatment improved life expectancy across all of the co-morbidity groups studied, 
including diabetes (LED 32.1 months vs 5.0 months), previous AMI (20.1 months vs 4.9 
months), history of heart failure (19.5 months vs 4.9 months), hypertension (16.6 months vs 
8.3 months), angina (16.2 months vs 5.0 months), and was greater for patients aged over than 
less than 65 years (11.3 months vs 5.7 months) (Table 2). For all categorical time points from 
randomisation and all patient subgroups (except for Q wave AMI at 25 years) there was an 
absolute and relative gain in life expectancy for ramipril (Supplement Tables 2 and 3). 
Moreover, for patients with diabetes, angina, previous heart failure and non Q-wave 
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infarction, ramipril treatment demonstrated increasing benefit in life expectancy with 
increasing time from randomisation. For all other subgroups, the gain in life expectancy for 
ramipril group increased up to 15 years from the time of randomisation. In particular, ramipril 
treatment had a greater extension of life for patients with than without co-morbidities, and 
was greatest for patients with diabetes (LED 32.1 95% CI -6.8 to 71.0) months; LER 1.54 95% 
CI 0.9 to 2.61) (Table 2).  
 
The effect of patients in the placebo group who could have switched to ramipril treatment 
was assessed according to intention to treat with ramipril treatment switching at 10% 
(patients refusing treatment) and with ramipril treatment switching at 30% (patients refusing 
treatment or drug intolerances), and across placebo switching of 0%, 10%, 20%, 40%, 60% and 
80%. Ramipril treatment compared with placebo reduced mortality for all parameters of 
potential ramipril and placebo switching and at all time points to 25 years except for, 10% 
ramipril switching at 15 years with 0% placebo switching, at 20 years for 0%, 10% and 20% 
placebo switching, 25 years for 0%, 10%, 20%, 40% placebo switching, and for 30% ramipril 
switching at 20 years for 0%, 10% and 20% placebo switching, and at 25 years for 0%, 10%, 
20% and 40% placebo switching (Figure 4). If 80% of patients in placebo group had switched 
to ramipril treatment after study closure, the dilution of the true treatment was estimated to 
be up to 28%, which would offer a maximum LED and LER of 33.6 months (95 % CI 28.4 to 
38.9) and 1.81 (95 % CI 1.57 to 2.09) during the follow-up from randomisation. Similar results 
were identified when evaluated by exclusion of any patient who had refused or was intolerant 





In this randomised study of the effect of ramipril treatment compared with placebo for 
patients with AMI and clinically defined heart failure followed up for nearly 30 years, we found 
that among 603 participants of the multicentre study, ramipril treatment was associated with 
substantial survival gains, which persisted beyond the blinded treatment allocation for up to 
15 years. Whilst the magnitude of the effect was greatest for patient with diabetes, it 
demonstrated a survival benefit for all co-morbidity subgroups studied. Overall, for every day 
a patient received ramipril, on average, their life was extended by a further day.  
 
Robust evidence supports the mortality benefit of ACE inhibition following AMI for patients 
with heart failure.19, 20 Moreover, international guidelines are clear in their recommendation 
for the prescription of ACE inhibitors following AMI.21 However, we are not aware of any study 
that has investigated the impact of ACE inhibition in patients with AMI and heart failure for 
longer than 12 years.22 Those studies which have studied ACE inhibition up to this time point 
have shown a beneficial effect in patients with heart failure 23, 24– a finding which our study 
builds upon – but such studies have reported intention-to-treat effects without disclosing 
rates of drug switching between trial arms or estimating the potential resultant counterfactual 
survival times.  
 
Our study found that ramipril had the greatest LED at about 15 years following the time from 
randomisation, and improved survival for the majority of combinations of switching of placebo 
and ramipril. Although the mortality benefit decreased over time, even after this period 
ramipril continued to convey a survival advantage, with a LER of 1.06 at final censorship at 
29.6 years from time of randomisation. We acknowledge, however, that although the 
difference in median lifetime between that study arms was 14.5 months, the LED was smaller 
12 
 
at 7.4 months and its lower confidence limit included the possibility of a negative effect. This 
was also reflected in the LER, which demonstrated a ratio <1 at the lower confidence limit. 
Therefore, although the point estimates for the effects of Ramipril on long-term survival were 
very favourable, it is entirely plausible that the population parameter could lie at any position 
in the range. 
 
We found that patients with diabetes, previous AMI, previous heart failure, hypertension, and 
angina each benefited, on average, from ACE inhibition. These findings were upheld in 
sensitivity analyses according to period of censorship. Notably, the relative risk of survival for 
patients with diabetes was increased by 54%, and supports other randomised evidence for 
the benefit of ACE inhibition in this population.25 Nonetheless, we found that women had a 
worse LED with ramipril treatment. We cannot explain this, though given that this finding has 
not been supported in other randomised controlled trials the finding may be due to small 
sample size effects. Equally, patients with Q wave AMI appeared not to benefit in the longer-
term from ramipril. However, for AIRE-S, we only tracked all-cause mortality and it is possible 
that ramipril reduced repeat AMI rather than improving left ventricular systolic function (and 
therefore survival) beyond the first year in this population.    
 
In light of the enduring effect of ramipril, our study suggests that ramipril conveys early 
mechanistic effects which translate into favourable long-term clinical outcomes. Indeed, in 
1994 the GISSI-3 investigators hypothesised that the process of adverse ventricular 
remodelling may be permanently modified by just 1 month of treatment with an ACE 
inhibitor.26 The TRACE study investigators found median survival to be 4.6 years for those 
initially given placebo versus 6.9 years for those who had received up to 2 years of 
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trandolapril.22 Whilst our study corrorborates these findings, we do not propose the 
discontinuation of ACE inhibition following myocardial infarction complicated by heart failure. 
Additionally, early survival may have enabled patients to be exposed to other treatments 
(such as intensive lipid lowering therapy, mineralocorticoid receptor antagonists, beta-
blockers, coronary revascularisation and cardiac rehabilitation), which may have become 
available after the end of the study and thus impacted favourably on their prognosis.  
 
We recognised the limitations of this study. We were not able to establish which medications 
patients may have received or had taken after the end of the trial, which could have biased 
the results in those in the ramipril arm had they received ACE inhibition and / or contemporary 
secondary prevention therapies compared with patients in the placebo arm. However, we 
estimated a wide range of potential effects of ramipril switching and ramipril discontinuation, 
and found largely consistent results, as well as a potential underestimation of the impact of 
ramipril on survival by nearly a third. The use of restricted mean survival time model could not 
account for the multitude of factors that could affect survival in both treatment arms over 
three decades including intercurrent illness, development of comorbidities, hospitalizations 
and changes in background medical therapy. We only had access to data for all-cause 
mortality, when ramipril may also have impacted on cardiovascular specific death and non-
fatal major cardiovascular and cerebrovascular endpoints. In the 1993 AIRE study, the 
diagnosis of heart failure was made on clinical grounds and there was no further detailed 
classification based on left ventricular function and functional status. This therefore prevents 
further insights into the long-term impact of Ramipril on survival in specific subgroups of 
patients according to these criteria. In addition, the lack of echocardiographic data at baseline, 
and reliance upon a clinical diagnosis could have misclassified patients, and it is possible that 
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some patients with clinical evidence of heart failure had preserved left ventricular systolic 
function. If this is the case, then our results support the notion of ACE inhibition for all patients 
with clinical heart failure following AMI. 
Safety endpoints such as hypotension, worsening renal function and hyperkalemia with ACIE 
therapy could not be captured. In 1993, for the AIRE study the diagnosis of heart failure was 
made on clinical grounds and whilst this could have misclassified patients, it is possible that 
some patients with clinical evidence of heart failure had preserved left ventricular systolic 
function and thus supports the notion of ACE inhibition for all patients with clinical heart 
failure following AMI.   
 
In conclusion, this study demonstrates that treatment with ramipril for about one year, when 
started early post AMI in patients with heart failure results in a survival benefit which is 
sustained over many years and offers, on average, an extension of life of an additional one 
year. These finding are evident across a range of patient groups studied and emphasise the 
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Table 1   Duration of treatment with blinded trial medication subdivided by cause for cessation 
of treatment. The decision as to use of ACE-inhibitor treatment beyond 28th February 1993 
was at the discretion of the attending clinician in the presence of on-going blinding to 
randomised treatment allocation. The reasons for discontinuation are not mutually exclusive.  
 
            
  











            
  Intolerance 28 (9.3%) 66 (21.9%) p<0.001 3.55 
  Inter-current disease 11 (3.7%) 13 (4.3%) NS 9.02 
  Patient refusal 10 (3.3%) 28 (9.3%) p=0.004 3.19 
  Failure to attend 3 (1.0%) 5 (1.7%) NS 2.73 
         
  Death 34 (11.0%) 19 (6.3%) p=0.032 5.51 
  Severe HF 41 (13.6%) 22 (7.3%) p=0.012 5.05 
  Other reasons 50 (16.6%) 31 (10.3%) p=0.022 7.22 
         
  AIRE Close 146 (48.5%) 139 (46.0%) NS 21.00 
         
  All Patients 301 (100%) 302 (100%)   12.87 





Table 2. Life expectancy difference, life expectancy ratio and median lifetime difference for patients randomly allocated to placebo or ramipril 
arms, by baseline patient characteristic  
 
Subgroup  No of patients  Life expectancy difference  
(months) (95% CI) 
  Life expectancy ratio 
(95% CI) 
 Difference of median 
lifetime (months) (95% CI) 
  Placebo  Ramipril       
Sex           
Male  230  225  10.4 (-9.8 to 30.5)  1.08 (0.93 to 1.26)  18.1 (16.7 to 19.6) 
Female  71  77   -0.3 (-33.1 to 32.6)  1.00 (0.76 to 1.32)  -0.9 (-3.7 to 1.9) 
Age (years)           
<65  137  136    5.7 (-22.5 to 33.8)  1.03 (0.88 to 1.22)  22.2 (20.4 to 24.1) 
>=65  163  166  11.3 (-6.7 to 29.2)  1.13 (0.93 to 1.37)  28.2 (26.2 to 30.2) 
Previous MI           
No  228  222    4.9 (-15.7 to 25.5)  1.04 (0.89 to 1.20)  7.7 (6.5 to 8.8) 
Yes  73  80  20.1 (-7.5 to 47.8)  1.25 (0.91 to 1.71)  50.8 (49.0 to 52.6) 
Hypertension           
No  237  219    8.3 (-11.8 to 28.5)  1.06 (0.92 to 1.23)   9.1 (8.0 to 10.2) 
Yes  64  83   16.6 (-14.6 to 47.7)  1.19 (0.85 to 1.68)  36.1 (34.2 to 38.1) 
Diabetes mellitus           
No  274  274    5.0 (-13.3 to 23.3)  1.04 (0.90 to 1.19)  4.3 (3.0 to 5.5) 
Yes  27  28  32.1 (-6.8 to 71.0)  1.54 (0.90 to 2.61)  43.3 (40.6 to 46.0) 
History of angina           
No  199  191    5.0 (-17.5 to 27.4)  1.03 (0.89 to 1.21)  21.7 (20.4 to 23.0) 
Yes  102  111  16.2 (-7.3 to 39.7)  1.19 (0.92 to 1.53)  35.1 (33.3 to 36.9) 
Previous HF           


















Yes  25  19   19.5 (-15.6 to 54.7)  1.38 (0.77 to 2.46)  59.5 (56.6 to 62.5) 
Type of infarction           
Anterior  176  176    8.7 (-14.3 to 31.7)  1.07 (0.89 to 1.28)  21.4 (19.9 to 22.9) 
Inferior  109  119    0.2 (-27.5 to 27.8)  1.00 (0.82 to 1.23)  -5.6 (-7.3 to -3.8) 
Q-wave  205  207   -2.3 (-23.8 to 19.3)  0.98 (0.84 to 1.15)  3.1 (1.8 to 4.4) 
Non Q-wave  83  89  23.2 (-6.5 to 52.8)  1.22 (0.94 to 1.57)  35.8 (33.3 to 38.2) 
All patients  301  302    7.4 (-10.0 to 24.9)  1.06 (0.93 to 1.21)  14.5 (13.2 to 15.8) 
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Figure 1 Kaplan-Meier survival curves for patients randomly allocated to receive placebo (301 patients) or ramipril (302) patients. RMSTs 
for placebo and ramipril arms and their differences were presented in months with 95% CI at 5, 10, 15, 20, and 25 years.  
 
Figure 2 Kaplan-Meier survival curves for patients randomly allocated to receive placebo (301 patients) or ramipril (302) patients, by 
subgroups. 
  
Figure 3 Life expectancy difference (a) and life expectancy ratio (b) for all patients and those under and above the median age of 65 years 
  
Figure 4  Adjusted hazard ratio from modelling of the dilution of the true treatment effect. Each scenario represents a proportion of 
patients in placebo arm switching to ramipril treatment. (a) ITT analysis for ramipril arm; (b) Patients refused treatment in ramipril arm (10%) 
were switched to placebo arm; (c) Patients refused treatment or drug intolerance in ramipril arm (30%) were switched to placebo arm. 
 
